Abstract | OBJECTIVE: METHODS: In two studies 534 women ≥12 years of age (mean 33.4) with 2-30 warts (mean 7.9) and total wart area ≥10 mm(2) (mean 166.3) were randomized (1:2:2) to placebo (106), imiquimod 2.5% (212) or 3.75% (216) creams applied once daily until complete clearance or a maximum of 8 weeks. RESULTS: For placebo, imiquimod 2.5% and 3.75%, respectively, complete clearance of all warts was achieved in 14.2%, 28.3%, and 36.6% of women (intent-to-treat, P = 0.008 imiquimod 2.5%, and P < 0.001 3.75% versus placebo). Mean changes in wart counts were -10.7%, -50.9%, and -63.5% (per-protocol, P < 0.001 each active versus placebo) and safety-related discontinuation rates 0.9%, 1.4%, and 2.3%. CONCLUSIONS:
Imiquimod 3.75% applied daily for up to 8 weeks was well tolerated and superior to placebo in treating women with external anogenital warts.
|
Authors | David A Baker, Daron G Ferris, Mark G Martens, Kenneth H Fife, Stephen K Tyring, Libby Edwards, Anita Nelson, Kevin Ault, Kenneth F Trofatter, Tiepu Liu, Sharon Levy, Jason Wu |
Journal | Infectious diseases in obstetrics and gynecology
(Infect Dis Obstet Gynecol)
Vol. 2011
Pg. 806105
( 2011)
ISSN: 1098-0997 [Electronic] Egypt |
PMID | 21876641
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Aminoquinolines
- Antiviral Agents
- Placebos
- Imiquimod
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Aminoquinolines
(administration & dosage, adverse effects)
- Antiviral Agents
(administration & dosage, adverse effects)
- Condylomata Acuminata
(drug therapy)
- Data Interpretation, Statistical
- Female
- Genital Diseases, Female
(drug therapy, virology)
- Humans
- Imiquimod
- Middle Aged
- Placebos
- Treatment Outcome
|